HALO Halozyme Stock Outlook 2026: A High-Margin Royalty Machine Running Against a Patent Clock
Halozyme (HALO) stock outlook 2026. A deep qualitative read on the ENHANZE subcutaneous drug-delivery royalty model, Darzalex SC concentration, partner dependence, the late-2020s patent-expiry cliff, buyback-driven capital allocation, and the metrics that actually matter.
HALO Halozyme US Stocks
